文献速递胸部肿瘤乳腺癌消化系统肿瘤

血浆循环肿瘤DNA比例在四种常见癌症类型中的预后价值:一项真实世界结局研究

Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study.
PubMed 文献 · Ann Oncol · 2022-10-05

本研究利用全国性去标识临床-基因组数据库中接受常规液体活检的1725例晚期癌症患者(mCRPC 198例、mBC 402例、aNSCLC 902例、mCRC 223例),基于全基因组单核苷酸多态性非整倍体计算循环肿瘤比例(TF)。TF≥10%在四种癌症中均与总生存期相关,多变量分析结果相似,提示其为独立预后生物标志物。

要点

  • TF≥10%在四种晚期癌症中均与总生存期相关,多变量分析结果相似
  • TF在较宽的界值范围内均保持一致的预后价值
  • 作者认为,经进一步前瞻性验证后,ctDNA TF有望纳入诊疗模式

核心结论

  • 血浆ctDNA肿瘤比例是四种晚期癌症中实用且独立的预后生物标志物,有望辅助围绕预期治疗结局的临床沟通。
  • 作者认为,经进一步前瞻性验证后,ctDNA TF可纳入诊疗模式,以依据患者层面的肿瘤生物学实现癌症治疗的精准升级与降级。

研究设计与样本

  • 研究利用全国性去标识临床-基因组数据库中的患者队列,这些患者因mCRPC、mBC、aNSCLC或mCRC在常规诊疗中接受液体活检。
  • TF基于全基因组单核苷酸多态性非整倍体计算,临床、疾病、实验室和治疗数据取自电子健康记录。
  • 共纳入1725例患者:mCRPC 198例、mBC 402例、aNSCLC 902例、mCRC 223例。
  • 在控制相关协变量后,按TF水平评估总生存期。

主要发现

  • 单变量分析中,TF≥10%在四种癌症类型中均与总生存期高度相关。
  • mCRPC:HR 3.3,95%CI 2.04-5.34,P < 0.001。
  • mBC:HR 2.4,95%CI 1.71-3.37,P < 0.001。
  • aNSCLC:HR 1.68,95%CI 1.34-2.1,P < 0.001。
  • mCRC:HR 2.11,95%CI 1.39-3.2,P < 0.001;TF的多变量评估点估计值与CI相似,提示其与生存期存在一致且独立的关联;探索性分析显示TF在较宽界值范围内均保持一致的预后价值。

关键数值与推荐

  • TF≥10%与总生存期相关:mCRPC HR 3.3(95%CI 2.04-5.34,P < 0.001),mBC HR 2.4(95%CI 1.71-3.37,P < 0.001),aNSCLC HR 1.68(95%CI 1.34-2.1,P < 0.001),mCRC HR 2.11(95%CI 1.39-3.2,P < 0.001)。
  • 多变量评估TF的点估计值与CI与单变量相似,提示其为独立预后关联;探索性分析显示TF在较宽界值范围内均保持预后价值。

临床怎么用

  • 原文未据此给出推荐;作者认为,经进一步前瞻性验证后,ctDNA TF可纳入诊疗模式,以依据患者层面的肿瘤生物学实现癌症治疗的精准升级与降级。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genomic analysis of circulating tumor DNA (ctDNA) is increasingly incorporated into the clinical management of patients with advanced cancer. Beyond tumor profiling, ctDNA analysis also can enable calculation of circulating tumor fraction (TF), which has previously been found to be prognostic. While most prognostic models in metastatic cancer are tumor type specific and require significant patient-level data, quantification of TF in ctDNA has the potential to serve as a pragmatic, tumor-agnostic prognostic tool. PATIENTS AND METHODS: This study utilized a cohort of patients in a nationwide de-identified clinico-genomic database with metastatic castration-resistant prostate cancer (mCRPC), metastatic breast cancer (mBC), advanced non-small-cell lung cancer (aNSCLC), or metastatic colorectal cancer (mCRC) undergoing liquid biopsy testing as part of routine care. TF was calculated based on single-nucleotide polymorphism aneuploidy across the genome. Clinical, disease, laboratory, and treatment data were captured from the electronic health record. Overall survival (OS) was evaluated by TF level while controlling for relevant covariables. RESULTS: A total of 1725 patients were included: 198 mCRPC, 402 mBC, 902 aNSCLC, and 223 mCRC. TF ≥10% was highly correlated with OS in univariable analyses for all cancer types: mCRPC [hazard ratio (HR) 3.3, 95% confidence interval (CI) 2.04-5.34, P < 0.001], mBC (HR 2.4, 95% CI 1.71-3.37, P < 0.001), aNSCLC (HR 1.68, 95% CI 1.34-2.1, P < 0.001), and mCRC (HR 2.11, 95% CI 1.39-3.2, P < 0.001). Multivariable assessments of TF had similar point estimates and CIs, suggesting a consistent and independent association with survival. Exploratory analysis showed that TF remained consistently prognostic across a wide range of cutpoints. CONCLUSIONS: Plasma ctDNA TF is a pragmatic, independent prognostic biomarker across four advanced cancers with potential to guide clinical conversations around expected treatment outcomes. With further prospective validation, ctDNA TF could be incorporated into care paradigms to enable precision escalation and de-escalation of cancer therapy based on patient-level tumor biology.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Reichert ZR, Morgan TM, Li G, et al. Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. Ann Oncol. 2022. PMID: 36208697. doi:10.1016/j.annonc.2022.09.163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。